Innoviva Inc - Asset Resilience Ratio
Innoviva Inc (INVA) has an Asset Resilience Ratio of 0.96% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check INVA strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Innoviva Inc's Asset Resilience Ratio has changed over time. See INVA net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Innoviva Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Innoviva Inc (INVA) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.73 Million | 0.96% |
| Total Liquid Assets | $15.73 Million | 0.96% |
Asset Resilience Insights
- Limited Liquidity: Innoviva Inc maintains only 0.96% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Innoviva Inc Industry Peers by Asset Resilience Ratio
Compare Innoviva Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Innoviva Inc (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Innoviva Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.96% | $15.73 Million | $1.64 Billion | -7.30pp |
| 2024-12-31 | 8.26% | $107.53 Million | $1.30 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $1.24 Billion | -- |
| 2022-12-31 | 32.73% | $403.01 Million | $1.23 Billion | -19.50pp |
| 2021-12-31 | 52.23% | $483.85 Million | $926.39 Million | +8.38pp |
| 2020-12-31 | 43.84% | $438.26 Million | $999.57 Million | +33.81pp |
| 2019-12-31 | 10.04% | $72.75 Million | $724.83 Million | +0.46pp |
| 2018-12-31 | 9.58% | $52.49 Million | $548.19 Million | -5.60pp |
| 2017-12-31 | 15.17% | $55.74 Million | $367.34 Million | +6.62pp |
| 2016-12-31 | 8.55% | $32.42 Million | $379.00 Million | +1.93pp |
| 2015-12-31 | 6.63% | $28.10 Million | $424.07 Million | -20.92pp |
| 2014-12-31 | 27.55% | $143.70 Million | $521.65 Million | -19.66pp |
| 2013-12-31 | 47.21% | $321.62 Million | $681.25 Million | +5.53pp |
| 2012-12-31 | 41.68% | $153.64 Million | $368.58 Million | -34.11pp |
| 2011-12-31 | 75.79% | $196.14 Million | $258.78 Million | +31.62pp |
| 2010-12-31 | 44.17% | $146.30 Million | $331.20 Million | -15.28pp |
| 2009-12-31 | 59.45% | $107.85 Million | $181.39 Million | +13.58pp |
| 2008-12-31 | 45.87% | $108.33 Million | $236.16 Million | +20.94pp |
| 2007-12-31 | 24.93% | $40.38 Million | $161.98 Million | -24.11pp |
| 2006-12-31 | 49.04% | $128.69 Million | $262.42 Million | -0.84pp |
| 2005-12-31 | 49.88% | $112.14 Million | $224.84 Million | -4.57pp |
| 2004-12-31 | 54.45% | $155.73 Million | $286.02 Million | +11.88pp |
| 2003-12-31 | 42.57% | $53.40 Million | $125.45 Million | +21.94pp |
| 2002-12-31 | 20.63% | $39.75 Million | $192.72 Million | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more